Work

Surrogate end points in lymphoma

Year: 2018

Type: editorial

Abstract: Overall survival is one of the most reliable end points to measure patients’ benefit from a drug or intervention in the context of a clinical trial. However, to determine a survival benefit, trials require enrolling a large number of patients who are followed for several years. This process may delay the introduction of effective treatment to patients with unmet medical needs, such as cancer, in addition to increasing the cost of drug development. In 1992, the United States Food and Drug Administration (FDA) instituted the accelerated approval mechanism that allowed drugs for serious conditions to be approved based on a surrogate end point [1].

Source: Annals of Oncology

DOI: 10.1093/annonc/mdy219

Authors: C.L. Batlevi, A. Younes

Institution: Memorial Sloan Kettering Cancer Center

Language: English

Topic: Statistical Methods in Clinical Trials

Subfield: Statistics and Probability

Field: Mathematics

Domain: Physical Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $5,080